Unmatched Logistics Solutions for the Life Sciences Industry

Precision medicine requires end-to-end traceability: everything from chain of custody, to chain of condition, to chain of identity. But the fragility of regenerative medicine therapies – and the need to more effectively manage risk– means that a fourth chain will soon be a regulatory requirement: the Chain of Compliance™. Enhanced traceability within the temperature-controlled and cold chain logistics distribution will soon be subjected to additional regulatory requirements due to the fragile aspect of the drug product and the disproportionate risk of improper cold chain management on the viability of the therapies. 

Early approvals of upcoming cell therapies have moved up manufacturing timelines for many firms in the biotech space. This blaze of approvals has been ignited by positive early clinical trial data, and now manufacturers are facing the substantial logistical challenges of scaling their products into the commercial stage.